首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Future Oncology

Future Oncology杂志,由Future Medicine Ltd.出版,于2005年创刊,Monthly,出版语言English,ISSN:1479-6694,E-ISSN:1744-8301。

投稿咨询
Future Oncology
Future Oncology
Future Oncology
SCI SCIE

杂志介绍

JCR分区
Q2
中科院分区
4区
影响因子
3.1
CiteScore
4.9
期刊收录
SCI、SCIE

Future Oncology(中文译名:《未来肿瘤学》),ISSN:1479-6694,EISSN:1744-8301,是Future Medicine Ltd.出版的国际性学术期刊,创刊于2005年,以Monthly形式稳定发行,2026年总发文量约290篇。该刊采用非OA开放访问,学科归属为ONCOLOGY。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达3.1,2025年期刊CiteScore为4.9,2025年期刊自引率约0%,在中科院期刊分区体系中位列医学大类4区,在所属学科领域具备高学术影响力与国际认可度。Future Oncology长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期偏慢,4-8周,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USACHINA MAINLAND、Italy、England、GERMANY (FED REP GER)、France、Spain等为核心发文国家与地区;UNIVERSITY OF TEXAS SYSTEMUNICANCER、PFIZER、HARVARD UNIVERSITY、SHANDONG FIRST MEDICAL UNIVERSITY & SHANDONG ACADEMY OF MEDICAL SCIENCES、SUN YAT SEN UNIVERSITY、UNIVERSITY OF LONDON等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
ONCOLOGY 肿瘤学
4区
否 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
ONCOLOGY 肿瘤学
4区
否 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
4区
ONCOLOGY 肿瘤学
4区
否 否

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q2 165 / 333

50.6

学科:ONCOLOGY SCIE Q3 185 / 333

44.59

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q3 181 / 328

45

学科:ONCOLOGY SCIE Q3 191 / 328

41.92


中国学者近期发文

1
Patterns of care in relapsed/refractory multiple myeloma in China: a real-world physician survey stud

Author:Wu, Di; Murali, Bhavna; Clark, Otavio; Luan, Luan; Hlavacek, Patrick; Chaudhary, Mohammed Ashraf; Aydin, Didem; DiBonaventura, Marco

Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 10, pp. 1213-1219. DOI: 10.1080/14796694.2026.2656394

2
SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCL

Author:Peters, Solange; Hochmair, Maximilian; Arbour, Kathryn C.; Rodriguez, Luis Paz-Ares; Reck, Martin; Leal, Ticiana; R. Lindsay, Colin; Shun, Lu; William, William Nassib; Spira, Alexander I.; Sabari, Joshua K.; Henning Grønberg, Bjørn; Nishio, Makoto; Burns, Timothy F.; Girard, Nicolas; Capuzzo, Frederico; Merced, Alyson; Fasnacht, Nicolas; Visseren-Grul, Carla; Negrao, Marcelo V

Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 9, pp. 1073-1082. DOI: 10.1080/14796694.2026.2651961

3
Comparison of concurrent chemoradiotherapy followed by immunotherapy and induction chemoimmunotherapy followed by radiotherapy in unresectable stage III NSCLC: a retrospective cohort stud

Author:Xu, Qinhao; Qi, Yana; Zhai, Xiaoyang; Chen, Feihu; Guo, Yingfan; Zhu, Hui

Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 7, pp. 819-829. DOI: 10.1080/14796694.2026.2637732

4
Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial design

Author:Yu, Evan Y.; Gratzke, Christian; Burotto, Mauricio; Zhang, Alison Y.; Levesque, Eric; Ortega, Francisco; Peer, Avivit; Vile, Donald; Chen, Zheng Hong; Song, Yue; Schloss, Charles; Todoric, Jelena; Garratt, Chris; Poehlein, Christian; Antonarakis, Emmanuel S.; Fizazi, Karim

Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 7, pp. 765-772. DOI: 10.1080/14796694.2025.2595914

5
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumor

Author:Schram, Alison M.; Park, John J.; Italiano, Antoine; Kitano, Shigehisa; Guo, Ye; Li, Jin; Bedard, Philippe L.; van Marcke, Cedric; Ko, Ryo; Lunger, Lukas; Klotz, Daniel M.; Hussain, Jo; Maier, Daniela; Erzen, Damijan; Planchard, David; Prenen, Hans; Clay, Timothy D.; Park, Joon O.; Kim, Hyung-Don; Hernando-Calvo, Alberto; Maruki, Yuta; Ponz-Sarvise, Mariano; Dumbrava, Ecaterina

Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 7, pp. 795-803. DOI: 10.1080/14796694.2026.2637740

6
Precision palliative care in advanced/recurrent esophageal cancer patients treated with anti-PD-1/PD-L1 immunotherapy (ESO-Shanghai 25): a randomized, phase III Tria

Author:Hao, Shengnan; Wang, Xiaomin; Ding, Huiping; Chen, Yun; Liu, Qi; Zhang, Junhua; Fan, Xingwen; Wu, Zhenhua; Lin, Ying; Xu, Xiaofang; Mao, Guangmin; Ai, Dashan; Deng, Jiaying; Zhu, Hongcheng; Ye, Jinjun; Mo, Miao; Hu, Zhihuang; Wang, Huijie; Cheng, Wenwu; Feng, Wei; Ling, Yiqun; Xu, Yufen; Du, Shisuo; Wang, Jialei; Zhao, Kuaile

Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 7, pp. 773-780. DOI: 10.1080/14796694.2026.2637738

7
Nivolumab plus chemotherapy in Asian people with advanced or recurrent stomach or gastroesophageal junction cancer (ATTRACTION-4 study): a plain language summar

Author:Chen, Li-Tzong; Kang, Yoon-Koo; Ryu, Min-Hee; Oh, Do-Youn; Oh, Sang Cheul; Rha, Sun Young; Lee, Keun-Wook; Omori, Takeshi; Shitara, Kohei; Sakuramoto, Shinichi; Chung, Ik-Joo; Yamaguchi, Kensei; Kato, Ken; Sym, Sun Jin; Kadowaki, Shigenori; Tsuji, Kunihiro; Chen, Jen-Shi; Bai, Li-Yuan; Oh, Sung-Yong; Choda, Yasuhiro; Yasui, Hisateru; Takeuchi, Kentaro; Hirashima, Yoshinori; Hagihara, Shunsuke; Boku, Narikazu

Journal: FUTURE ONCOLOGY. 2026; Vol. 22, Issue 6, pp. 625-642. DOI: 10.1080/14796694.2026.2622806

8
Efficacy and safety of anti-CLDN18.2 therapies in advanced or metastatic gastric, gastro-oesophageal junction, and oesophageal carcinomas with CLDN18.2 positivity: a systematic review and meta-analysi

Author:Zhang, Yaping; Kao, Shangbin; Li, Dian; Yan, Canlong; Huang, Biao; Fang, Hongming

Journal: FUTURE ONCOLOGY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14796694.2026.2659354

9
Significance of the HALP score in patients with primary liver cancer undergoing hepatectomy: a meta-analysi

Author:Zhang, Min; Xu, Kailin; Ye, Jufeng

Journal: FUTURE ONCOLOGY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14796694.2026.2646142

10
Concurrent immunotherapy is associated with increased radiation necrosis risk in lung cancer patients with brain metastases treated with stereotactic radiosurger

Author:Du, Guochang; Li, Wanjing; Li, Ji; Yu, Jinming; Zhu, Hui

Journal: FUTURE ONCOLOGY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14796694.2026.2642933


在线咨询

Future Oncology

国际简称:FUTURE ONCOL参考译名:未来肿瘤学

年发文量:290 CiteScore:4.9 是否预警:否 Gold OA文章占比:23.77% 研究类文章占比:79.31%

杂志社联系方式:FUTURE MEDICINE LTD, UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, ENGLAND, N3 1QB

Future Oncology